| Abstract: |
The abilities of Escherichia coli‐ derived human interferon gamma (IFN‐γ) and E. coii‐ derived human interferon‐μA (IFN‐μA) or ‐μ2 (IFN‐μ2) to augment natural killer (NK) cytotoxicity were compared. When low concentrations (less than 10 antiviral units/ml) of interferons were used, and equal numbers of antiviral units of E. coli‐derived IFN‐γ and E. coli‐ derived IFN‐μA or IFN‐μ2. were compared for their ability to augment NK. E. coli‐derived IFN‐γ was found to be more active in augmenting NK against the K562targets, than E. coli‐ derived IFN‐μA or IFN‐μ2. Antiviral units in these experiments were determined by the standard cytopathic effect assay using vesicular stomatitis virus (VSV)‐challenged human fibroblasts, trisomic for chromosome 21. However, when these interferons were compared on a weight basis (ng/ml) or on a molar basis, their ability to augment NK against the K562 targets was comparable. These differences in the relative abilities of these interferons (when their concentrations were expressed in antiviral units/ml) to augment NK, were due to an approximately 100‐fold difference in their specific activities (antiviral units per mg of interferon). These were 1. 8 × 106 units/mg for E. coli‐derived IFN‐γ, 2. 0 × 108 units/mg for E. coli‐derived IFN‐μA,and 1. 8 × 108 units/mg for E. coli‐derived IFN‐μ2. At concentrations higher than 10 units/ml. all these interferons showed a similar ability to augment NK. Studies on the kinetics on the augmentation revealed that in vitro treatment with E. coli‐derived IFN‐γ for several hours was necessary for augmentation of NK against targets from haemopoietic human tumour cell lines (K562, Daudi). In contrast, alpha interferons were able to augment NK after treatment in vitro for significantly shorter periods (30 min or less with certain donors), Augmentation of NK cytotoxicity of human peripheral blood mononuclear leucocytes by E. coli‐derived IFN‐γ was not accompanied by the induction of interleukin 2 (IL‐2) production, suggesting that 1L. ‐2 is not involved in the augmentation of NK by 1FN‐γ, A monoclonal antibody specific for human IFN‐γ blocked augmentation of NK by E. coli‐derived IFN‐γ and natural IFN‐γ ‐ but not by E. coli‐derived IFN‐μA or staphylococcal enterotoxin A (SEA). Pretreatment (14 h at 37°C) of effector cells with this anti‐IFN‐γ monoclonal antibody or addition of this antibody directly into the 15chromium release assay had no effect on NK cytotoxicity, suggesting that constitutively produced IFN‐γ is not required for maintaining NK cytotoxicity. Copyright © 1986, Wiley Blackwell. All rights reserved |
| Keywords: |
human cell; drug efficacy; alpha interferon; interleukin 2; cell line; cytotoxicity; monoclonal antibody; antibodies, monoclonal; kinetics; gamma interferon; escherichia coli; recombinant proteins; natural killer cell; killer cells, natural; cytotoxicity, immunologic; immunomodulation; drug cytotoxicity; adjuvants, immunologic; lymphocytotoxicity; leukemia, erythroblastic, acute; intoxication; interferon type ii; immune sera; topical drug administration; target cell destruction; antibody-dependent cell cytotoxicity; human; priority journal; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; blood and hemopoietic system
|
